Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab vs Rituximab in ITP Patients
NCT07297563Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2026
- Primary completion
- Nov 2027
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of daratumumab in immune thrombocytopenia (ITP) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Overall Response Rate at 12 weeks. Started Jan 2026; status: recruiting.
02
Drugs
daratumumab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT07297563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07297563.